Furthermore, SIRT6 promotes glycolysis in erlotinib-resistant NSCLC cells through the HIF-1α/HK2 signaling axis, which is the mechanism of drug resistance. The gene discussed is SIRT6; the disease is non-small cell lung carcinoma.